Loading...
Market
Patient count for sickle cell gene therapy by end of 2025
4
Resolution / Starting Odds
Less than 100 • 34%
100-500 • 33%
More than 500 • 33%
Treatment centers or public health records
Story
Kendric Cromer Receives First Sickle Cell Gene Therapy; CRISPR Shows Safety, Efficacy in Blindness
May 6, 2024, 02:00 PM
Recent advancements in gene therapy have shown significant progress in treating various inherited diseases. Kendric Cromer, a 12-year-old boy from the Washington, D.C. area, has become the first person to receive a newly approved gene therapy for sickle cell disease, expressing his desire to be cured. Clinical trials have demonstrated the efficacy of CRISPR gene editing in treating inherited forms of blindness, with improvements in vision for several patients and showing safety and early evidence of efficacy. Additionally, gene therapies are also being developed for other conditions, such as skeletal defects and inherited retinal diseases, showing early signs of effectiveness and safety.
View original story
Similar markets
10-20 • 33%
21-30 • 33%
31+ • 34%
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,001 to 30,000 • 25%
More than 30,000 • 25%
Less than 10 hospitals • 33%
10 to 50 hospitals • 33%
More than 50 hospitals • 34%
Widely adopted • 25%
Moderately adopted • 25%
Rarely adopted • 25%
Not adopted • 25%
None • 20%
1-2 • 20%
3-4 • 20%
5-6 • 20%
7 or more • 20%
None • 25%
1-2 • 25%
3-5 • 25%
More than 5 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10 • 25%
10-20 • 25%
21-50 • 25%
More than 50 • 25%
None • 20%
1 • 20%
2-5 • 20%
6-10 • 20%
More than 10 • 20%
Under 100 hospitals • 33%
100-500 hospitals • 34%
Over 500 hospitals • 33%